Anthropic's IPO forces Wall Street to put a price on AI extinction risk

By Zendoric · October 9, 2026.

In its Markets Daily newsletter, Bloomberg raises a dilemma that until now lived in academic papers and conference panels: how to put a price on a company that part of the AI research community considers capable of contributing to human extinction. The trigger is the preparation of the stock market debut of Anthropic, the company behind the Claude models, which according to the publication is shaping up to be one of the largest IPOs (initial public offering, the process of listing on a stock exchange for the first time) in the tech sector.

Anthropic's own chief executive, Dario Amodei, has publicly acknowledged the risks of his own technology: the possibility that humans lose control over advanced AI systems and the danger that these could be used to enhance cyberattacks or bioterrorism programs, as Bloomberg reports. The publication adds that some AI researchers put the probability of an extinction scenario at 10% or more, a figure that has circulated in the public debate on safety for some time, without any methodological consensus on how to calculate it or who has the authority to do so.

What is striking is not the risk itself —Anthropic has spent years building its corporate identity around safety, with its responsible scaling policy and dangerous capability evaluations before each release— but where it now lands: the IPO prospectus. When a company goes public, risk stops being a public relations argument or a chapter in an internal report and becomes material information subject to disclosure obligations, with legal consequences if it is omitted or downplayed. Wall Street is going to have to assign a number to something that until now was, above all, a philosophical discussion.

Our reading is that this may, paradoxically, be good news for AI governance. As long as the risk of a model running out of control lives only in the discourse of its own creators, there is no external mechanism to discipline it. The moment it enters a listing prospectus, in come securities lawyers, rating agencies, institutional funds and analysts with a mandate —and a fiduciary duty— to ask how that risk is audited, what safeguards exist and what happens if they fail. It is a mechanism similar, with nuances, to the one that has already brought the most advanced AI technology into the regulatory arena: as soon as a technical risk acquires market value or regulatory relevance, it stops being merely a technical matter and starts to have a price, a policy and someone accountable for it.

The counterpoint, and it is worth saying so honestly, is the usual one in these transitions: being listed creates pressure to grow revenue quarter after quarter, and that pressure does not always sit well with caution. OpenAI already showed, with its restructuring toward a for-profit structure, that the tension between founding mission and capital market demands is real and does not resolve itself. Anthropic will have to demonstrate, results after results, that its safety promise is not just a competitive advantage over less cautious rivals, but a commitment that survives shareholder pressure.

At Zendoric we believe that this kind of friction —markets, regulators and labs forced to agree on how to measure and mitigate a risk that was previously discussed only in the abstract— is part of the path toward an AI that, over the long term, cures diseases and multiplies abundance without derailing along the way. But the final price of that IPO, and the governance clauses that accompany it, will say far more about whether that caution is real than any public statement from its chief executive.